| 194.38 -10.27 (-5.02%) | 04-25 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 278.47  |
1-year : | 313.28 |
| Resists | First : | 238.42 |
Second : | 268.22 |
| Pivot price | 228.36 |
|||
| Supports | First : | 190.22 |
Second : | 158.26 |
| MAs | MA(5) : | 208.58 |
MA(20) : | 233.97 |
| MA(100) : | 233.44 |
MA(250) : | 214.56 |
|
| MACD | MACD : | -11.4 |
Signal : | -6.9 |
| %K %D | K(14,3) : | 18.5 |
D(3) : | 23 |
| RSI | RSI(14): 28.8 |
|||
| 52-week | High : | 322.67 | Low : | 119.76 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ MDGL ] has closed below the lower bollinger band by 1.7%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 36.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 200.72 - 202.07 | 202.07 - 203.18 |
| Low: | 187.71 - 188.99 | 188.99 - 190.04 |
| Close: | 192.48 - 194.59 | 194.59 - 196.33 |
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
Thu, 25 Apr 2024
Madrigal Pharmaceuticals (NASDAQ:MDGL) Trading Down 6% - MarketBeat
Wed, 24 Apr 2024
Madrigal: 2 Challenges To Overcome To Maintain NASH 'First Mover' Advantage (NASDAQ:MDGL) - Seeking Alpha
Mon, 22 Apr 2024
Madrigal Pharmaceuticals Becomes Oversold (MDGL) - Nasdaq
Wed, 03 Apr 2024
Madrigal Pharmaceuticals Inc Director Kenneth Bate Sells 32,489 Shares - Yahoo Finance
Tue, 26 Mar 2024
Here's 1 Huge New Reason to Buy Madrigal Pharmaceuticals Stock - The Motley Fool
Fri, 15 Mar 2024
Madrigal's (MDGL) Rezdiffra Gets FDA Approval to Treat NASH Liver Disease - Bloomberg
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 21 (M) |
| Shares Float | 13 (M) |
| Held by Insiders | 9.2 (%) |
| Held by Institutions | 94.7 (%) |
| Shares Short | 3,360 (K) |
| Shares Short P.Month | 3,460 (K) |
| EPS | -19.99 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 20.38 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -47.5 % |
| Return on Equity (ttm) | -124 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -18.12 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -324 (M) |
| Levered Free Cash Flow | -192 (M) |
| PE Ratio | -9.73 |
| PEG Ratio | 0 |
| Price to Book value | 9.53 |
| Price to Sales | 0 |
| Price to Cash Flow | -12.58 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|